Cargando…
Lack of UGT polymorphism association with idasanutlin pharmacokinetics in solid tumor patients
PURPOSE: Idasanutlin is a selective small-molecule MDM2 antagonist. It activates the tumor suppressor TP53 and is in phase 3 clinical trial for acute myeloid leukemia. Nonclinical studies have shown that glucuronidation is the major metabolizing mechanism for idasanutlin and UGT1A3 is the major meta...
Autores principales: | So, W. Venus, Ou Yang, Tai-Hsien, Yang, Xing, Zhi, Jianguo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6373577/ https://www.ncbi.nlm.nih.gov/pubmed/30511219 http://dx.doi.org/10.1007/s00280-018-3741-2 |
Ejemplares similares
-
Population pharmacokinetic analysis of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) in adult patients with solid tumors
por: Aregbe, Abdulateef O., et al.
Publicado: (2012) -
Common UGT1A9 polymorphisms do not have a clinically meaningful impact on the apparent oral clearance of dapagliflozin in type 2 diabetes mellitus
por: Naagaard, M. Daniel, et al.
Publicado: (2022) -
Meta-Analysis Reveals a Lack of Association between UGT2B17 Deletion Polymorphism and Tumor Susceptibility
por: Deng, Xiaheng, et al.
Publicado: (2014) -
Effects of ABCB1, UGT1A1, and UGT1A9 Genetic Polymorphisms on the Pharmacokinetics of Sitafloxacin Granules in Healthy Subjects
por: Sun, Lu‐Ning, et al.
Publicado: (2020) -
Rationale for Considering Oral Idasanutlin as a Therapeutic Option for COVID-19 Patients
por: Zauli, Giorgio, et al.
Publicado: (2020)